keyword
MENU ▼
Read by QxMD icon Read
search

Bimatoprost

keyword
https://www.readbyqxmd.com/read/29244069/impact-of-comprehensive-minimally-invasive-multimodal-aesthetic-treatment-on-satisfaction-with-facial-appearance-the-harmony-study
#1
Susan H Weinkle, W Philip Werschler, Craig F Teller, Jonathan M Sykes, Ava Shamban, Alexander Rivkin, Vic A Narurkar, Michael S Kaminer, Steven Dayan, Joel L Cohen, Conor J Gallagher
Background: Individuals seeking aesthetic treatment have concerns regarding multiple facial areas. Objectives: Assess the aesthetic impact and satisfaction achieved with a multimodal approach to aesthetic treatment using a combination of minimally invasive treatments. Methods: Prospective, multicenter, rater-blinded, 4-month HARMONY study evaluated patient satisfaction and aesthetic impact of a combination of fillers (VYC-20L, HYC-24L, and HYC-24L+), onabotulinumtoxinA, and bimatoprost...
December 13, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/29220066/periorbital-changes-associated-with-topical-prostaglandins-analogues-in-a-hispanic-population
#2
Ferdinand Rodríguez-Agramonte, Juan Carlos Jiménez, José Raúl Montes
OBJECTIVE: To describe the prevalent side effects of prostaglandin analogues (PA) in a Hispanic population and their effect on quality of life (QOL). PATIENTS AND METHODS: This is a cross-sectional study conducted in a tertiary medical facility in which patients were evaluated in a single visit. Total of 14 participants in the study, 10 women and 4 men. Ages ranged from 26-78 years old. Subjects underwent a single full Oculoplastic evaluation by two physicians; one was blinded on patient medical history and assessed for PA side effects...
December 2017: Puerto Rico Health Sciences Journal
https://www.readbyqxmd.com/read/29200831/efficacy-and-safety-of-fixed-combination-bimatoprost-timolol-ophthalmic-solution
#3
COMMENT
Suk Bae Moon, Sang Beom Han
No abstract text is available yet for this article.
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29151684/glaucoma-medication-preferences-among-glaucoma-specialists-in-mexico
#4
Gabriel Lazcano-Gomez, Daniela Alvarez-Ascencio, Cindy Haro-Zuno, Mauricio Turati-Acosta, Magdalena Garcia-Huerta, Jesus Jimenez-Arroyo, Rafael Castañeda-Diez, Armando Castillejos-Chevez, Roberto Gonzalez-Salinas, Francisca Dominguez-Dueñas, Jesus Jimenez-Roman
Aim: To determine the glaucoma specialists' preferences for the different brands of topical glaucoma medications available in Mexico. Materials and methods: A web-based survey was sent to 150 board-certified glaucoma specialists in Mexico, with 14 questions related to brand preferences for all glaucoma medications available in Mexico. Participants were asked to select each glaucoma medication class by brand and to state the factors leading to their choice. Results: Data from 111 (74%) glaucoma specialists were collected...
September 2017: Journal of Current Glaucoma Practice
https://www.readbyqxmd.com/read/29143575/determination-of-illegal-adulteration-of-dietary-supplements-with-synthetic-hair-growth-compounds-by-uplc-and-lc-q-tof-ms
#5
Ji Hyun Lee, Gihaeng Kang, Han Na Park, Jihee Kim, Nam Sook Kim, Seongsoo Park, Sung-Kwan Park, Sun Young Baek, Hoil Kang
In this study, we developed a UPLC-PDA and LC-Q-TOF/MS method to identify and measure the following prohibited substances that may be found in dietary supplements:triaminodil, minoxidil, bimatoprost, alimemazine, diphenylcyclopropenone, α-tradiol, finasteride, methyltestosterone, spironolatone, flutamide, cyproterone, dutasteride, and testosterone 17-propionate.The method was validated according to International Conference on Harmonization guidelines in terms of specificity, linearity, accuracy, precision, LOD, LOQ, recovery, and stability...
December 14, 2017: Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment
https://www.readbyqxmd.com/read/29057117/a-masked-randomized-phase-3-comparison-of-triple-fixed-combination-bimatoprost-brimonidine-timolol-versus-fixed-combination-brimonidine-timolol-for-lowering-intraocular-pressure
#6
Curt Hartleben, Juan Camilo Parra, Amy Batoosingh, Paula Bernstein, Margot Goodkin
OBJECTIVE: To evaluate the efficacy and safety of triple fixed-combination bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% (TFC) versus dual fixed-combination brimonidine 0.2%/timolol 0.5% (DFC) in primary open-angle glaucoma and ocular hypertension. METHODS: Patients with intraocular pressure (IOP) ≥23 and ≤34 mmHg were randomized to twice-daily TFC or DFC. The primary variable is the change in worse eye mean IOP from baseline at week 12 (modified intent-to-treat (mITT) population)...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/29034590/bimatoprost-ophthalmic-solution-in-facial-vitiligo
#7
Abhijeet K Jha, Smita Prasad, Rajesh Sinha
BACKGROUND: Vitiligo is one of the commonest pigmentary disorders characterized by destruction of melanocytes. AIM: To evaluate the efficacy of topical bimatoprost ophthalmic solution in stable facial vitiligo. MATERIAL AND METHODS: Eight cases of stable facial vitiligo were treated with bimatoprost 0.03% ophthalmic solution once daily for 12 weeks. Photographic records were taken at 2 weeks follow-up along with dermoscopic (Polarized, 10×) evaluation...
October 15, 2017: Journal of Cosmetic Dermatology
https://www.readbyqxmd.com/read/29026287/ocular-pharmacokinetics-and-tolerability-of-bimatoprost-ophthalmic-solutions-administered-once-or-twice-daily-in-rabbits-and-clinical-dosing-implications
#8
Jie Shen, Margot L Goodkin, Warren Tong, Mayssa Attar
PURPOSE: Fixed-combination medications can benefit patients requiring multiple agents to lower their intraocular pressure (IOP), but combining agents with complementary mechanisms of action is challenging if their dosing frequency differs. This study compares in vivo pharmacokinetic and ocular tolerability of bimatoprost 0.01% ophthalmic solutions dosed once or twice daily. Reports of twice-daily dosing in glaucoma patients are also reviewed. METHODS: New Zealand White rabbits were administered bimatoprost 0...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28980566/-multi-level-analysis-of-the-prevalence-of-pseudoexfoliative-syndrome-and-pseudoexfoliative-glaucoma
#9
O N Kuleshova, E A Pichikova, A K Lasareva, S V Aydagulova, V V Dulidova, E V Egorova, V V Chernykh
Epidemiological investigation of pseudoexfoliative syndrome (PEX) as a glaucoma predictor is necessary for antiglaucoma treatment planning. AIM: To study the prevalence of PEX and pseudoexfoliative glaucoma (PXFG) among healthy people, naïve patients, and patients under observation as well as to evaluate the hypotensive efficacy of bimatoprost/timolol fixed combination (FCBT) over 4 months in PXFG. MATERIAL AND METHODS: Epidemiological analysis, ophthalmological examination, statistical analysis...
2017: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/28961640/fractional-resurfacing-and-topical-bimatoprost-for-the-treatment-of-laser-induced-postinflammatory-hypopigmentation-on-the-lower-extremities
#10
Ashley Regis, Jennifer MacGregor, Anne Chapas
No abstract text is available yet for this article.
September 28, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28861351/efficacy-and-safety-of-bimatoprost-in-glaucoma-and-ocular-hypertension-in-non-responder-patients
#11
Nicholas Brennan, Mohammad H Dehabadi, Sandhya Nair, Ana Quartilho, Catey Bunce, Ian Reekie, Raal Obikpo
AIM: To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (IOP)on current therapy. METHODS: Pre- and post-switch IOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in IOP post-pre switch was analyzed using a 2-sided Student's paired t-test at the 5% significance level...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28794615/evaluating-intraocular-pressure-lowering-solutions-for-the-treatment-of-open-angle-glaucoma-comparison-between-bimatoprost-0-03-and-bimatoprost-0-01-an-observational-switch-study
#12
Sarita S Deshpande, Sriram Sonty, Afzal Ahmad
PURPOSE: The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.01% solution in patients with primary open-angle glaucoma (POAG), who were switched from bimatoprost 0.03% solution, compared to patients with POAG who continued on bimatoprost 0.03% solution. METHODS: A retrospective review evaluated 35 patients (35 right eyes [OD], 34 left eyes [OS]) who remained on bimatoprost 0.03% and 30 patients (27 OD, 30 OS) who were switched to bimatoprost 0...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28744094/patient-considerations-in-ocular-hypertension-role-of-bimatoprost-ophthalmic-solution
#13
REVIEW
Daniel Lee, Anand V Mantravadi, Jonathan S Myers
Glaucoma is a leading cause of irreversible blindness worldwide. The reduction of intraocular pressure has been well established as an effective treatment to prevent both the development and the progression of all forms of glaucoma. Bimatoprost 0.03% ophthalmic solution, introduced in 2001, is a synthetic prostamide with the unique mechanism of improving both uveoscleral and trabecular outflow. Comparative studies with other pharmacotherapies have shown favorable results for bimatoprost as a potent ocular hypotensive agent that is generally well tolerated...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28727804/effects-of-pre-surgical-administration-of-prostaglandin-analogs-on-the-outcome-of-trabeculectomy
#14
Takako Miki, Tomoko Naito, Miyuki Fujiwara, Ryoichi Araki, Rieko Kiyoi, Yusuke Shiode, Atsushi Fujiwara, Yuki Morizane, Fumio Shiraga
For primary open angle glaucoma (POAG), laser treatment or surgery is used when the target intraocular pressure (IOP) cannot be achieved by pharmacological agents, such as prostaglandin (PG) analogs; these drugs also have varied effects. We retrospectively reviewed the medical records of 74 POAG patients (74 eyes) whose IOP was inadequately controlled by PG analogs (bimatoprost [13 eyes], latanoprost [34 eyes], tafluprost [11 eyes], and travoprost [16 eyes]) and underwent primary trabeculectomy. The proportion of patients with no recurrent IOP elevation within 24 months post-trabeculectomy was significantly (P < 0...
2017: PloS One
https://www.readbyqxmd.com/read/28716077/periorbital-changes-associated-with-prostaglandin-analogs-in-korean-patients
#15
Hee Weon Kim, Youn Joo Choi, Kyung Wha Lee, Min Joung Lee
BACKGROUND: Prostaglandin analogs (PGAs) are commonly used to treat glaucoma because of their powerful intraocular pressure lowering effect. However, various periorbital changes associated with the use of PGAs have been reported. We investigated the incidence of periorbital changes in Korean patients who were treated with PGAs, and analyzed clinical factors associated with superior sulcus deepening. METHODS: This study included 58 glaucoma patients who were treated with latanoprost, travoprost, or bimatoprost unilaterally...
July 17, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28681570/the-effect-of-cutaneous-prostaglandin-application-on-nail-growth-nail-brittleness-and-intraocular-pressure
#16
David J Palmer, Andrew Scheman, Angelo P Tanna, Alex Bueno
BACKGROUND: Bimatoprost has known adnexal activity and was observed to increase nail growth at two clinical centers. OBJECTIVES: In this randomized, double-blinded, placebo-controlled pilot study, we examine the effect of bimatoprost (Lumigan 0.01%), applied bid to the proximal nail fold on nail growth, nail brittleness, and intraocular pressure. METHODS: Bimatoprost drops were placed on the proximal nail folds of 45 subjects on one hand (medication group) and vehicle drops to the other hand (control group)...
July 6, 2017: Journal of Cosmetic Dermatology
https://www.readbyqxmd.com/read/28616797/the-efficacy-and-safety-of-bimatoprost-timolol-maleate-latanoprost-timolol-maleate-and-travoprost-timolol-maleate-fixed-combinations-on-24-h-iop
#17
Suzan Guven Yilmaz, Cumali Degirmenci, Yunus Emre Karakoyun, Emil Yusifov, Halil Ates
PURPOSE: To evaluate the effect of bimatoprost/timolol maleate fixed combination (BTFC), latanoprost/timolol maleate fixed combination (LTFC), and travoprost/timolol maleate fixed combination (TTFC) on 24-h intraocular pressure (IOP) in patients with open-angle glaucoma. METHODS: This prospective, observer-masked, randomized study included 50 patients with primary open-angle glaucoma. All patients were using hypotensive lipids and timolol maleate fixed combination treatment for ≥4 weeks and had an IOP ≤ 21 mmHg...
June 14, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28562438/retrospective-evaluation-of-topical-bimatoprost-and-iris-pigmentation-change
#18
Lisa A Zaleski-Larsen, Nadine H Ruth, Sabrina G Fabi
BACKGROUND: Topical bimatoprost is a topical prostaglandin analog originally used to treat glaucoma and more recently used to cosmetically induce hypertrichosis of the eyelashes. Iris pigmentation change has been noted in the treatment of glaucoma but has not been assessed with the cosmetic periorbital application of bimatoprost. OBJECTIVE: To evaluate for iris pigmentation change with the long-term cosmetic use of topical bimatoprost. MATERIALS AND METHODS: A retrospective chart review in a cosmetic dermatology practice of women (N = 50) who consistently purchased topical bimatoprost over an average of 4...
May 25, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28528010/long-term-safety-and-efficacy-of-a-sustained-release-bimatoprost-ocular-ring
#19
James D Brandt, Harvey B DuBiner, Robert Benza, Kenneth N Sall, Gary A Walker, Charles P Semba
No abstract text is available yet for this article.
May 17, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28496310/patient-satisfaction-with-fixed-combination-bimatoprost-timolol-ophthalmic-solution-a-survey-study-in-patients-with-glaucoma-in-china
#20
Xinghuai Sun, Mingkai Lin, Xuanchu Duan, Chun Zhang, Jian Ming
BACKGROUND: Poor adherence to treatment is a problem in glaucoma, and patient dissatisfaction with topical glaucoma medication is a barrier to adherence. The objective of this study was to evaluate glaucoma patients' satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution (BTFC). METHODS: This observational, multicenter study was conducted in China in adults with glaucoma treated with BTFC for 1-3 months. Five hundred patients answered a questionnaire concerning their demographic characteristics, history of glaucoma and topical glaucoma treatment, and use of BTFC...
2017: Patient Preference and Adherence
keyword
keyword
27282
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"